Pivotal bioequivalence trial of glucagon, delivered by the Glucagon Emergency Management (GEM) system

Trial Profile

Pivotal bioequivalence trial of glucagon, delivered by the Glucagon Emergency Management (GEM) system

Planning
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Glucagon (Primary)
  • Indications Hypoglycaemia
  • Focus Pharmacokinetics; Registrational
  • Sponsors Biodel
  • Most Recent Events

    • 15 Dec 2014 New trial record
    • 04 Dec 2014 This design of this trial and the comparator selected will be based on data from a phase I crossover trial in volunteers (clinical trial 700252270), according to a Biodel media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top